Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.

Détails

ID Serval
serval:BIB_961E17EB7D71
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.
Périodique
American journal of transplantation
Auteur(s)
Pittet L.F., Verolet C.M., McLin V.A., Wildhaber B.E., Rodriguez M., Cherpillod P., Kaiser L., Siegrist C.A., Posfay-Barbe K.M.
ISSN
1600-6143 (Electronic)
ISSN-L
1600-6135
Statut éditorial
Publié
Date de publication
03/2019
Peer-reviewed
Oui
Volume
19
Numéro
3
Pages
844-854
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Live-attenuated vaccines are currently contraindicated in solid-organ transplant recipients. However, the risk of vaccine-preventable infections is lifelong, and can be particularly severe after transplantation. In this prospective interventional national cohort study, 44 pediatric liver transplant recipients with measles IgG antibodies <150 IU/L (below seroprotection threshold) received measles-mumps-rubella vaccine (MMR) at a median of 6.3 years posttransplantation (interquartile range, 4.0 to 10.9). A maximum of two additional doses were administered in nonresponders or when seroprotection was lost. Vaccine responses occurred in 98% (95% confidence interval [CI], 88-100) of patients. Seroprotection at 1-, 2-, and 3-year follow-up reached 62% (95% CI, 45-78), 86% (95% CI, 70-95), and 89% (95% CI, 67-99), respectively. All patients responded appropriately to the booster dose(s). Vaccinations were well tolerated and no serious adverse event attributable to vaccination was identified during the 8-week follow-up period (or later), using a multimodal approach including standardized telephone interviews, diarized side effect reporting, and monitoring of vaccinal virus shedding. We conclude that live attenuated MMR vaccine can be administered in liver transplant recipients fulfilling specific eligibility criteria (>1 year posttransplantation, low immunosuppression, lymphocyte count ≥0.75 G/L), inducing seroprotection in most subjects. (Clinicaltrials.gov number NCT01770119).
Mots-clé
clinical research/practice, clinical trial, infection and infectious agents-viral, infectious disease, liver transplantation/hepatology, pediatrics, vaccine
Pubmed
Web of science
Création de la notice
08/10/2018 8:13
Dernière modification de la notice
20/08/2019 14:58
Données d'usage